Enterprise Value
-57.42M
Cash
120.1M
Avg Qtr Burn
-29.14M
Short % of Float
1.29%
Insider Ownership
4.71%
Institutional Own.
54.26%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AFM13 (Acimtamig)+ cbNK cells Details Cancer, Non-Hodgkin lymphoma | Phase 2 Data readout | |
AFM13 (Acimtamig) Details Peripheral T cell cancer , Cancer | Phase 2 Initiation | |
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
AFM13 (Acimtamig) + AB-101 Details Cancer, Lymphoma, Hodgkin Lymphoma, peripheral T-cell lymphomas | Phase 1/2 Data readout | |
AFM28 Details Cancer, Blood cancer, Leukemia, Acute myeloid leukemia | Phase 1 Data readout | |
AFM24 (tumor target EGFR) Monotherapy Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer | Failed Discontinued | |
RO7297089 (formerly AFM26) Details Multiple myeloma, Cancer | Failed Discontinued |